Advertisement
Advertisement
U.S. Markets close in 4 hrs 3 mins
Advertisement
Advertisement
Advertisement
Advertisement

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.50-0.10 (-1.04%)
As of 10:25AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.60
Open9.97
Bid9.50 x 1800
Ask9.85 x 1200
Day's Range9.50 - 9.62
52 Week Range8.61 - 14.00
Volume1,271
Avg. Volume22,380
Market Cap213.016M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateDec 14, 2021 - Dec 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.51
  • GlobeNewswire

    CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

    FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically test over 3,000 FTD patients at multiple sites in seven countriesThere are currently no FDA-approved treatments for FTD CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven ins

  • Simply Wall St.

    Do Institutions Own Centogene N.V. (NASDAQ:CNTG) Shares?

    The big shareholder groups in Centogene N.V. ( NASDAQ:CNTG ) have power over the company. Large companies usually have...

  • GlobeNewswire

    CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

    Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the WorldCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (Nasdaq: TWST), a Company enabling customers to succeed through

Advertisement
Advertisement